

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known			
				Application Number	10/003211-Conf. #6970		
11	IFORMATIC	N DIS	SCLOSURE	Filing Date	October 31, 2001		
STATEMENT BY APPLICANT				First Named Inventor	Jeffrey L. BROWNING		
				Art Unit	1642- 1643		
(Use as many sheets as necessary)			necessary)	Examiner Name	C. H. Yaen		
Sheet	1	of	1	Attorney Docket Number	BGNA013CN		

U.S. PATENT DOCUMENTS							
Examiner Initials*			Publication Date Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines.	
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
टर	B1	WO-92/00329-A1	01-09-1992	Biogen, Inc., et al.		┢
	B2	WO-94/13808-A2		Biogen, Inc., et al.		┰
CY	B3	WO-97/03687-A1		Biogen, Inc.		Н

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	er Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate) and of the article (when appropriate) are also as a supplication and of the article (when appropriate) and of the article (when appropriate) are also as a supplication and of the article (when appropriate) are also as a supplication and of the article (when appropriate) are also as a supplication and of the article (when appropriate) are also as a supplication and of the article (when appropriate) are also as a supplication and article (when appropriate) are also as a supplication		T ²			
CY	C1	http://reutershealth.com/wellconnected/doc63.html				
	C2	Browning, Jeffrey L., et al., "Signaling through the Lymphotoxin β Receptor Induces the Death of Some Adenocarcinoma Tumor Lines," <i>J. Exp. Med.</i> , Vol. 183:867-878 (1996)				
	C3	Browning, Jeffrey L., et al., "Characterization of Surface Lymphotoxin Forms," The Journal of Immunology, Vol. 154:33-46 (1995)				
	C4	Gyorfy, Zs., et al., "Alteration of the TNF Sensitivity and Membrane Viscosity of Target Cells," Eur. Cytokine Netw., Vol. 7(2):167 (1996)				
	C5	Mendlovic, Shlomo, et al., "Induction of a Systemic Lupus Erythematosus-like Disease in Mice by a Common Human Anti-DNA Idiotype," <i>Proc. Natl. Acad. Sci. USA, Vol.</i> 85:2260-2264 (1988)				
	C6	Rennert, P.D., et al., "Normal Development of Lymph Nodes is Disrupted by Soluble LT beta Receptor - Ig Fusion Protein," Eur. Cytokine Netw., Vol. 7(2):167 (1996				
	C7	Smolen, Josef S., "Therapy of systemic lupus erythematosus: a look into the future," Arthritis Res, Vol. 4(suppl. 3):S25-S30 (2002)				
T	C8	Trethewey, Pat, "Systemic Lupus Erythematosus," <i>Dimensions of Critical Care Nursing, Vol.</i> 23(3):111-115 (2004)				
ĽΥ	C9	International Search Report Docket No. PCT/US97/19436, dated May 28, 1998				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner 1	Date		7	/
Signature CAN A OHY	1	-	//	/~/
Signature Christian H	Considered		10	106 I
,				

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.